Structural Basis for the Regulation of PPAR gamma Activity by Imatinib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Jun Young | - |
dc.contributor.author | Kim, Hyun-Jung | - |
dc.contributor.author | Han, Byung Woo | - |
dc.date.available | 2020-04-02T08:21:00Z | - |
dc.date.issued | 2019-10 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/37859 | - |
dc.description.abstract | Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor gamma (PPAR gamma) phosphorylation at Ser245 to evaluate possibilities of antidiabetic drug repositioning, imatinib was determined as a PPAR gamma antagonist ligand. However, it is not well understood how imatinib binds to PPAR gamma or would improve insulin sensitivity without classical agonism. Here, we report the crystal structure of the PPAR gamma R288A mutant in complex with imatinib. Imatinib bound to Arm2 and Arm3 regions in the ligand-binding domain (LBD) of PPAR gamma, of which the Arm3 region is closely related to the inhibition of PPAR gamma phosphorylation at Ser245. The binding of imatinib in LBD induced a stable conformation of helix H2 ' and the Omega loop compared with the ligand-free state. In contrast, imatinib does not interact with Tyr473 on PPAR gamma helix H12, which is important for the classical agonism associated with side effects. Our study provides new structural insights into the PPAR gamma regulation by imatinib and may contribute to the development of new antidiabetic drugs targeting PPAR gamma while minimizing known side effects. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Structural Basis for the Regulation of PPAR gamma Activity by Imatinib | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/molecules24193562 | - |
dc.identifier.bibliographicCitation | Molecules, v.24, no.19 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000496242300147 | - |
dc.identifier.scopusid | 2-s2.0-85072909741 | - |
dc.citation.number | 19 | - |
dc.citation.title | Molecules | - |
dc.citation.volume | 24 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | imatinib | - |
dc.subject.keywordAuthor | PPAR gamma | - |
dc.subject.keywordAuthor | antidiabetic drug | - |
dc.subject.keywordAuthor | type 2 diabetes | - |
dc.subject.keywordAuthor | crystal structure | - |
dc.subject.keywordPlus | ABL TYROSINE KINASE | - |
dc.subject.keywordPlus | LIGAND-BINDING | - |
dc.subject.keywordPlus | AGONISTS | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.